Company intelligence / Profile preview

Tryl Therapeutics

Kelowna, British Columbia, Canada

Ownership: Private
Development stage: Other

Overview

Tryp has ongoing Phase 2a trials for binge eating disorder at the University of Florida and fibromyalgia at the University of Michigan using TRP-8802 (synthetic oral psilocybin). TRP-8803 (IV-infused psilocin) completed Phase 2 clinical trials for binge eating disorder and is in Phase 1 trials for healthy volunteers in Australia

Therapeutic areas: EndocrinologyNeurologyRheumatologyGastroenterologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

University of Michigan (fibromyalgia clinical trial)University of Florida (binge eating disorder clinical trial)Calvert Labs (exploratory psilocybin studies)Fluence (psychotherapeutic training for clinical trials)Exopharm Limited (strategic collaboration)

Beyond the preview

Go deeper on Tryl Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tryl Therapeutics.

Explore the full profile